Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity
Launched by BIOCODEX · Dec 9, 2020
Trial Information
Current as of October 20, 2025
Completed
Keywords
ClinConnect Summary
This observatory evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity, after a one-month treatment with Bibidobacterium longum 35624, 1x10\^9 CFU/capsule, 1 capsule/day.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female, at least 18 years of age
- • Gastroenterology consultation for an Irritable Bowel Syndrome according to Rome IV criteria
- • Having received a first prescription of Bifidobacterium longum 35624 during the consultation (independently of participation in the observatory)
- • Informed and having declared his/her non-opposition to the study.
- Exclusion Criteria:
- • Not having a good enough command of reading and comprehension of the French language to correctly complete the questionnaires and the notebook
- • Having already taken Bifidobacterium longum 35624
- • Having received probiotics or antibiotics within 2 weeks previous
- • Having started within the last 7 days a treatment that can interfere with the investigator's evaluation of the investigational product under investigation
- • Participant in another trial
- • Pregnant or breastfeeding women
- • Being under guardianship or curator.
- • Not having a good enough command of reading and comprehension of the French language to correctly complete the questionnaires and the notebook
About Biocodex
Biocodex is a global biopharmaceutical company dedicated to improving patient health through innovative therapies and high-quality healthcare solutions. With a strong focus on gut health, neurology, and critical care, Biocodex invests in research and development to advance its portfolio of products, including prescription medications and over-the-counter remedies. Committed to scientific excellence and ethical standards, Biocodex collaborates with healthcare professionals and stakeholders to enhance patient outcomes and foster a healthier future. Its robust clinical trial activities demonstrate a dedication to evidence-based medicine and continuous improvement in therapeutic practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bobigny, France
Patients applied
Trial Officials
Gyasi K Johnson, PhD
Study Director
Biocodex
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials